Skip to main navigation
  • DEFLATEHAE.COM
  • Investors & News
  • Careers
  • Contact
Pharvaris N.V. homepage
  • Disease Focus
  • Community Commitment
  • Scientific Approach
    • Our Science
    • Pipeline
  • Scientific Publications
  • About Pharvaris
Pharvaris N.V. homepage
  • Disease Focus
  • Community Commitment
  • Scientific Approach
    • Our Science
    • Pipeline
  • Scientific Publications
  • About Pharvaris
  • DEFLATEHAE.COM
  • Investors & News
  • Careers
  • Contact

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

European Academy of Allergy & Clinical Immunology (EAACI) Congress 2023

Jun 9 - Jun 11, 2023

Supporting Materials

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms 1.1 MB
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial 700.6 KB

Location

Hamburg, Germany
Pharvaris N.V.

©2026 Pharvaris N.V. © All Rights Reserved

Menu
  • Privacy Policy
  • Clinical Trial Privacy Notice
  • Global Privacy Laws
  • Terms of Use
CONTACT US
FOLLOW US